Chronic idiopathic axonal neuropathy and pain, treated with the endogenous lipid mediator palmitoylethanolamide: a case collection
Open Access
- 1 September 2013
- journal article
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. 6, 49-53
Abstract
Peer reviewed article authored by (Keppel Hesselink JM). Read article or submit your manuscript for publishing.Keywords
This publication has 24 references indexed in Scilit:
- Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common ColdInternational Journal of Inflammation, 2013
- Chronic Idiopathic Axonal Polyneuropathy Is Associated With the Metabolic SyndromeDiabetes Care, 2013
- Palmitoylethanolamide is a New Possible Pharmacological Treatment for the Inflammation Associated with TraumaMini-Reviews in Medicinal Chemistry, 2013
- Receptors for acylethanolamides—GPR55 and GPR119Prostaglandins & Other Lipid Mediators, 2009
- The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factorsPain, 2008
- The search for the palmitoylethanolamide receptorLife Sciences, 2005
- Drug therapy for chronic idiopathic axonal polyneuropathy2004
- Sorbitol malabsorption and nonspecific abdominal symptoms in type II diabetesMetabolism, 1995
- A proposed autacoid mechanism controlling mastocyte behaviourInflammation Research, 1993
- Late-Life Chronic Peripheral Neuropathy of Obscure NatureArchives of Neurology, 1982